WELCURE DRUGS & PHARMACEUTICALS LTD.

Welcure Drugs & Pharmaceuticals Ltd announced that its Board of Directors has accepted the resignation of Ms. Palak Jain from the positions of Company Secretary, Compliance Officer, and Key Managerial Personnel. The resignation is effective from the close of business hours on June 19, 2026, and is due to personal reasons and other professional commitments. The company has filed the necessary disclosures as per SEBI regulations.

Welcure Drugs & Pharmaceuticals Ltd has announced its audited standalone financial results for the quarter and year ended March 31, 2026. The announcement was made following a Board of Directors meeting held on May 29, 2026. The auditors have issued an unmodified opinion on the financial results. However, the auditor has emphasized on uncertainties related to trade receivables, trade payables, and loans and advances, and the lack of MSME creditor bifurcation support.

Welcure Drugs & Pharmaceuticals Ltd announced the audited standalone financial results for the quarter and year ended March 31, 2026. The board of directors approved the results in a meeting held on May 29, 2026. The auditor's report contains an unmodified opinion but raises concerns regarding trade receivables, payables, loans, advances, and inventory valuation.

Welcure Drugs & Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial results for the quarter/year ended March 31, 2026. The board will also review the audit report from the statutory auditors and approve the audited financial statements, including the balance sheet, profit and loss statement, and cash flow statement for the same period.

Welcure Drugs & Pharmaceuticals Ltd has announced the closure of the trading window for all Designated Persons, Designated Employees, Specified Persons and their immediate relatives. The closure is in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the Company's Internal Code of Conduct. The trading window will remain closed from April 01, 2026 till the expiry of 48 hours after the Declaration of Audited Standalone Financial Results of 4th Quarter and Annual Year Ended March 31, 2026 become generally available information.

Welcure Drugs & Pharmaceuticals Ltd has announced its unaudited financial results for the 3rd quarter ended on 31st December, 2025. The Board of Directors approved the financial results in a meeting held on 12th February, 2026. The company's financial results were reviewed by Sarang Shivajirao Chavan & Associates, the independent auditor.

The Board of Directors of Welcure Drugs & Pharmaceuticals Ltd. met on 12th February, 2026, and approved the unaudited financial results for the quarter ended 31st December, 2025. The results were reviewed by Sarang Shivajirao Chavan & Associates, the independent auditor, in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's management is responsible for the preparation of the financial statements in accordance with Ind AS 34 and other accounting principles generally accepted in India.

Welcure Drugs & Pharmaceuticals Ltd has announced that its Board of Directors will meet on February 12, 2026, to consider and approve the un-audited financial results for the quarter and nine months ended December 31, 2025. The meeting will be held at the company's registered office in New Delhi, India. The trading window for dealing in the securities of the company for all designated persons, designated employees, specified persons, and their immediate relatives was closed from January 01, 2026, till the expiry of 48 hours after the declaration of the unaudited standalone financial results for the quarter and nine months ended on December 31, 2025.

Welcure Drugs & Pharmaceuticals Ltd has announced the closure of its trading window for all Designated Persons, Designated Employees, Specified Persons, and their immediate relatives. The closure will commence from January 01, 2026, and will last until 48 hours after the declaration of unaudited Standalone Financial Results for the quarter ended December 31, 2025. This decision is in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's Internal Code of Conduct.

Welcure Drugs & Pharmaceuticals Ltd announced the outcome of its Board of Directors meeting held on December 06, 2025. The company informed about the abortion of the equity investment proposal with Telexcell Trade PTE LTD, Singapore, due to the inability to reach a mutually acceptable framework. The proposed Agro-Pharma Research Laboratory project and fundraising through QIP have been dropped due to strategic priorities. The company completed export-sourcing orders worth INR 299.91 crore through domestic sales to the originally intended parties. A definitive mandate for third-party sourcing and procurement services with Fortune Sagar Impex Company Limited, Thailand, has been discontinued. The meeting commenced at 10:00 AM and concluded at 11:00 AM.